{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:17:44Z","timestamp":1788419864310,"version":"build-2803163510"},"reference-count":49,"publisher":"American Association for Cancer Research (AACR)","issue":"5","funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","award":["DE-AC02-06CH11357. 3.7.2.2"],"award-info":[{"award-number":["DE-AC02-06CH11357. 3.7.2.2"]}],"id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Acute myeloid leukemia (AML) is an aggressive blood disorder characterized by rapid growth of poorly differentiated myeloid cells. Gain-of-function mutations in isocitrate dehydrogenases (IDH) are detected in \u223c20% of AML and \u223c80% of secondary gliomas. Mutant IDH1\/2 isoenzymes acquire neomorphic activity to produce 2-hydroxyglutarate (2-HG) oncometabolite, resulting in hypermethylated DNA and histones, altered gene expression, and blocked differentiation of hematopoietic progenitors. Here, we present preclinical development of LY3410738, an oral, dual IDH1\/2 inhibitor with potential to penetrate the blood\u2013brain barrier. LY3410738 covalently inhibited mutated IDH1\/2, reduced 2-HG levels at low nanomolar concentrations in human AML and glioma models, and demonstrated efficacy in AML patient-derived xenografts (PDX) in vivo, inducing myeloid differentiation. LY3410738 retained in vitro activity in cancer models with acquired secondary IDH1\/2 mutations conferring resistance to ivosidenib and enasidenib. LY3410738 synergized and was well tolerated with standard-of-care regimens such as cytarabine, azacitidine, venetoclax, or midostaurin in IDH1\/2-mutated AML PDXs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>LY3410738 represents a promising advancement in the treatment of IDH1\/2-mutated AML. Its irreversible binding and targeting of both IDH1\/2 isoforms, coupled with sustained activity against mIDH1\/2 with acquired second-site resistance mutations, distinguishes LY3410738 from clinically available IDH inhibitors and suggests therapeutic potential for patients with AML resistant to standard IDH-based treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-25-0379","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:16:28Z","timestamp":1784819788000},"page":"774-795","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["LY3410738, a Covalent Inhibitor of Mutant IDH1\/2, Is Effective in Acute Myeloid Leukemia Preclinical Models"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6028-2096","authenticated-orcid":false,"given":"Nathan A.","family":"Brooks","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0979-026X","authenticated-orcid":false,"given":"Anna","family":"Skwarska","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, University of Texas MD Anderson, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-4635","authenticated-orcid":false,"given":"Vivian","family":"Salama","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, University of Texas MD Anderson, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7918-4229","authenticated-orcid":false,"given":"Mark H.","family":"Bender","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9343-7314","authenticated-orcid":false,"given":"Lisa","family":"Kays","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2996-0054","authenticated-orcid":false,"given":"Robin I.","family":"DeWalt","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0546-526X","authenticated-orcid":false,"given":"Bryan","family":"Perria","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7915-4070","authenticated-orcid":false,"given":"Deepti","family":"Thete","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4046-1989","authenticated-orcid":false,"given":"Jason R.","family":"Manro","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3939-8019","authenticated-orcid":false,"given":"Rachel","family":"Cavitt","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8038-6568","authenticated-orcid":false,"given":"Rebecca","family":"Leon","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1804-6405","authenticated-orcid":false,"given":"Sandra","family":"Gomez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6145-0691","authenticated-orcid":false,"given":"Raquel","family":"Torres","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9310-7629","authenticated-orcid":false,"given":"John M.","family":"Strelow","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2083-0618","authenticated-orcid":false,"given":"Paul","family":"Milligan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9296-5405","authenticated-orcid":false,"given":"Kate","family":"Newell","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3650-9808","authenticated-orcid":false,"given":"Kenneth D.","family":"Roth","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-2032","authenticated-orcid":false,"given":"Jean-Emmanuel","family":"Sarry","sequence":"additional","affiliation":[{"name":"3Centre de Recherches en Canc\u00e9rologie de Toulouse, Universit\u00e9 de Toulouse, Toulouse, France."},{"name":"4LabEx Toucan, Toulouse, France."},{"name":"5\u00c9quipe Labellis\u00e9e Ligue Nationale Contre le Cancer, Toulouse, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4354-0731","authenticated-orcid":false,"given":"Steven M.","family":"Chan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 6 , University Health Network, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7351-0016","authenticated-orcid":false,"given":"Danalyn Manglicmot","family":"Lagutan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9954-2965","authenticated-orcid":false,"given":"Richard","family":"Romero","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1596-2790","authenticated-orcid":false,"given":"Stephen","family":"Antonysamy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0478-6069","authenticated-orcid":false,"given":"Robert L.","family":"Johnson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5647-4090","authenticated-orcid":false,"given":"Xueqian","family":"Gong","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5352-6389","authenticated-orcid":false,"given":"Renato A.","family":"Bauer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1677-7674","authenticated-orcid":false,"given":"Timothy P.","family":"Burkholder","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0592-1022","authenticated-orcid":false,"given":"Patric J.","family":"Hahn","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6866-4290","authenticated-orcid":false,"given":"Zoran","family":"Rankovic","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7399-8383","authenticated-orcid":false,"given":"Serge L.","family":"Boulet","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, University of Texas MD Anderson, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, University of Texas MD Anderson, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6753-0071","authenticated-orcid":false,"given":"Raymond","family":"Gilmour","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly and Company 1 , Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"2026090303081518400_bib1","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1158\/1078-0432.CCR-13-1333","article-title":"Molecular pathways: isocitrate dehydrogenase mutations in cancer","volume":"22","author":"Clark","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026090303081518400_bib2","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/leu.2014.124","article-title":"DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies","volume":"28","author":"Im","year":"2014","journal-title":"Leukemia"},{"key":"2026090303081518400_bib3","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"2026090303081518400_bib4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026090303081518400_bib5","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"key":"2026090303081518400_bib6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/leu.2016.275","article-title":"Isocitrate dehydrogenase mutations in myeloid malignancies","volume":"31","author":"Medeiros","year":"2017","journal-title":"Leukemia"},{"key":"2026090303081518400_bib7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1146\/annurev-biochem-061516-044732","article-title":"Isocitrate dehydrogenase mutation and (R)-2-Hydroxyglutarate: from basic discovery to therapeutics development","volume":"86","author":"Dang","year":"2017","journal-title":"Annu Rev Biochem"},{"key":"2026090303081518400_bib8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41408-021-00497-1","article-title":"Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026090303081518400_bib9","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41375-024-02246-2","article-title":"Management of isocitrate dehydrogenase 1\/2 mutated acute myeloid leukemia","volume":"38","author":"Fruchtman","year":"2024","journal-title":"Leukemia"},{"key":"2026090303081518400_bib10","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026090303081518400_bib11","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026090303081518400_bib12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature09132","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"2026090303081518400_bib13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"2026090303081518400_bib14","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026090303081518400_bib15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1021\/ml300225h","article-title":"Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo","volume":"3","author":"Popovici-Muller","year":"2012","journal-title":"ACS Med Chem Lett"},{"key":"2026090303081518400_bib16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","article-title":"Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers","volume":"9","author":"Popovici-Muller","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"2026090303081518400_bib17","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1158\/1078-0432.CCR-23-2234","article-title":"FDA approval summary: ivosidenib in combination with azacitidine for treatment of patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation","volume":"30","author":"Woods","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026090303081518400_bib18","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1021\/acs.jmedchem.9b01423","article-title":"Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor","volume":"63","author":"Caravella","year":"2020","journal-title":"J Med Chem"},{"key":"2026090303081518400_bib19","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discov"},{"key":"2026090303081518400_bib20","doi-asserted-by":"publisher","first-page":"931462","DOI":"10.3389\/fonc.2022.931462","article-title":"The molecular mechanisms of resistance to IDH inhibitors in acute myeloid leukemia","volume":"12","author":"Zhuang","year":"2022","journal-title":"Front Oncol"},{"key":"2026090303081518400_bib21","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","article-title":"Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML","volume":"4","author":"Choe","year":"2020","journal-title":"Blood Adv"},{"key":"2026090303081518400_bib22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41586-018-0251-7","article-title":"Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations","volume":"559","author":"Intlekofer","year":"2018","journal-title":"Nature"},{"key":"2026090303081518400_bib23","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov"},{"key":"2026090303081518400_bib24","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1\/2 study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026090303081518400_bib25","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"2026090303081518400_bib26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1084\/jem.20150736","article-title":"Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia","volume":"213","author":"Boutzen","year":"2016","journal-title":"J Exp Med"},{"key":"2026090303081518400_bib27","doi-asserted-by":"publisher","first-page":"e20200924","DOI":"10.1084\/jem.20200924","article-title":"Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia","volume":"218","author":"Stuani","year":"2021","journal-title":"J Exp Med"},{"issue":"8_Supplement","key":"2026090303081518400_bib28","doi-asserted-by":"publisher","first-page":"CT026","DOI":"10.1158\/1538-7445.AM2023-CT026","article-title":"Abstract CT026: a first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies","volume":"83","author":"Dinardo","year":"2023","journal-title":"Cancer Res"},{"key":"2026090303081518400_bib29","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.str.2016.12.017","article-title":"Allosteric mutant IDH1 inhibitors reveal mechanisms for IDH1 mutant and isoform selectivity","volume":"25","author":"Xie","year":"2017","journal-title":"Structure"},{"key":"2026090303081518400_bib30","doi-asserted-by":"publisher","first-page":"7877","DOI":"10.1038\/s41467-024-51692-0","article-title":"Biostructural, biochemical and biophysical studies of mutant IDH1","volume":"15","author":"McCoy","year":"2024","journal-title":"Nat Commun"},{"key":"2026090303081518400_bib31","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1038\/s41467-021-22874-x","article-title":"Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"2026090303081518400_bib32","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"2026090303081518400_bib33","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1182\/bloodadvances.2023009854","article-title":"Olutasidenib: from bench to bedside","volume":"7","author":"Venugopal","year":"2023","journal-title":"Blood Adv"},{"key":"2026090303081518400_bib34","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"de Botton","year":"2023","journal-title":"Blood Adv"},{"key":"2026090303081518400_bib35","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood"},{"key":"2026090303081518400_bib36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.23736\/S0026-4806.20.07024-X","article-title":"Enasidenib and ivosidenib in AML","volume":"111","author":"Martelli","year":"2020","journal-title":"Minerva Med"},{"key":"2026090303081518400_bib37","doi-asserted-by":"publisher","first-page":"494","DOI":"10.6004\/jadpro.2019.10.5.7","article-title":"Ivosidenib: IDH1 inhibitor for the treatment of acute myeloid leukemia","volume":"10","author":"Merchant","year":"2019","journal-title":"J Adv Pract Oncol"},{"key":"2026090303081518400_bib38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41408-023-00915-6","article-title":"Response patterns and impact of MRD in patients with IDH1\/2-mutated AML treated with venetoclax and hypomethylating agents","volume":"13","author":"Hammond","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026090303081518400_bib39","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-018-0115-6","article-title":"Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib","volume":"24","author":"Quek","year":"2018","journal-title":"Nat Med"},{"key":"2026090303081518400_bib40","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1200\/JCO-25-00640","article-title":"Outcomes of frontline triplet regimens with a hypomethylating agent, venetoclax, and isocitrate dehydrogenase inhibitor for intensive chemotherapy-ineligible patients with isocitrate dehydrogenase-mutated AML","volume":"43","author":"DiNardo","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026090303081518400_bib41","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A phase Ib\/II study of ivosidenib with venetoclax \u00b1 azacitidine in IDH1-mutated myeloid malignancies","volume":"4","author":"Lachowiez","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"2026090303081518400_bib42","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"key":"2026090303081518400_bib43","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1158\/1078-0432.CCR-25-0174","article-title":"Final results from a first-in-human phase I study of the dual isocitrate dehydrogenase (IDH) 1\/2 inhibitor, LY3410738, in advanced solid tumors harboring IDH1 or IDH2 mutations","volume":"31","author":"Harding","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026090303081518400_bib44","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026090303081518400_bib45","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"key":"2026090303081518400_bib46","doi-asserted-by":"publisher","first-page":"e0224137","DOI":"10.1371\/journal.pone.0224137","article-title":"Statistical determination of synergy based on Bliss definition of drugs independence","volume":"14","author":"Demidenko","year":"2019","journal-title":"PLoS One"},{"key":"2026090303081518400_bib47","doi-asserted-by":"publisher","first-page":"12984","DOI":"10.1038\/s41598-022-16933-6","article-title":"CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts","volume":"12","author":"Huang","year":"2022","journal-title":"Sci Rep"},{"key":"2026090303081518400_bib48","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.2967\/jnumed.119.237230","article-title":"177Lu-Lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-hodgkin lymphoma","volume":"61","author":"Malenge","year":"2020","journal-title":"J Nucl Med"},{"key":"2026090303081518400_bib49","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1158\/2767-9764.CRC-23-0243","article-title":"Statistical assessment of drug synergy from in vivo combination studies using mouse tumor models","volume":"3","author":"Mao","year":"2023","journal-title":"Cancer Res Commun"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0379\/3815360\/bcd-25-0379.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0379\/3822071\/bcd-25-0379.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/5\/774\/3825005\/bcd-25-0379.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/5\/774\/3825005\/bcd-25-0379.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:08:23Z","timestamp":1788419303000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/5\/774\/787651\/LY3410738-a-Covalent-Inhibitor-of-Mutant-IDH1-2-Is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7,23]]},"published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0379","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]}}}